Glioblastoma Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Glioblastoma stocks.

Recent Signals

Date Stock Signal Type
2021-05-11 AFMD Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-05-11 CCXI Lower Bollinger Band Walk Weakness
2021-05-11 CCXI Calm After Storm Range Contraction
2021-05-11 CCXI Narrow Range Bar Range Contraction
2021-05-11 CLDX 20 DMA Resistance Bearish
2021-05-11 CLDX 50 DMA Support Bullish
2021-05-11 CLLS Lower Bollinger Band Walk Weakness
2021-05-11 CLLS Jack-in-the-Box Bearish Bearish Swing Setup
2021-05-11 CLRB Stochastic Buy Signal Bullish
2021-05-11 CNSP Lower Bollinger Band Walk Weakness
2021-05-11 CNSP Bollinger Band Squeeze Range Contraction
2021-05-11 CNSP Stochastic Buy Signal Bullish
2021-05-11 DCPH New 52 Week Low Weakness
2021-05-11 DCPH Lower Bollinger Band Walk Weakness
2021-05-11 DCPH Slingshot Bearish Bearish Swing Setup
2021-05-11 DFFN Fell Below 20 DMA Bearish
2021-05-11 MBRX Bollinger Band Squeeze Range Contraction
2021-05-11 MBRX Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-05-11 NVCR New Downtrend Bearish
2021-05-11 PRLD Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-05-11 PRLD Stochastic Sell Signal Bearish
2021-05-11 PSTV Calm After Storm Range Contraction
2021-05-11 RGLS NR7 Range Contraction
2021-05-11 RGLS Calm After Storm Range Contraction
2021-05-11 RGLS Narrow Range Bar Range Contraction
2021-05-11 SGMO Lower Bollinger Band Walk Weakness
2021-05-11 SGMO Bullish Engulfing Bullish
2021-05-11 TCON Lower Bollinger Band Walk Weakness
2021-05-11 VBLT 20 DMA Support Bullish
2021-05-11 VBLT 50 DMA Support Bullish

Recent News for Glioblastoma Stocks

Date Stock Title
May 12 CCXI Kessler Topaz Meltzer & Check, LLP: Important Deadline Reminder for ChemoCentryx, Inc. Investors in Securities Fraud Class Action Lawsuit
May 11 CCXI SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of ChemoCentryx, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2021 - CCXI
May 11 CLLS Sanofi and Cellectis partner for alemtuzumab in CAR T-cells trials
May 11 CLLS Cellectis and Sanofi partner on alemtuzumab as lymphodepletion agent for allogeneic CAR-T
May 11 CCXI Scott+Scott Attorneys at Law LLP Alerts Investors to Securities Class Action Against ChemoCentryx, Inc. (CCXI) and July 6 Deadline
May 11 CCXI CCXI LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving ChemoCentryx, Inc.
May 11 CCXI SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ChemoCentryx, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
May 11 VBLT Vascular Biogenics' (VBLT) CEO Dror Harats on Q1 2021 Results - Earnings Call Transcript
May 11 CCXI Lawsuits Filed Against BLU, GOEV and CCXI - Jakubowitz Law Pursues Shareholders Claims
May 11 CCXI The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ROOT, FGEN and CCXI
May 11 CCXI CCXI CLASS ACTION FILED: Contact HAGENS BERMAN to Recover Losses Due to Alleged Securities Fraud
May 11 VBLT Vascular Biogenics (VBLT) Reports Q1 Loss, Lags Revenue Estimates
May 11 CNSP CNS Pharmaceuticals to Present at the Q2 Virtual Investor Summit
May 11 PRLD Prelude Therapeutics EPS misses by $0.05
May 11 MBRX Moleculin Biotech to Present at the Q2 Virtual Investor Summit
May 11 MBRX WPD pharmaceuticals to get $6.7M grant for development of Leukemia treatment
May 11 MBRX WPD Pharmaceuticals to Receive $6.7 Million Grant for Development of Annamycin Drug Candidate
May 11 PRLD Prelude Therapeutics Announces First Quarter 2021 Financial Results and Operations Update
May 11 VBLT VBL Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 11 CCXI CLASS ACTION UPDATE for RMO, CCXI and SKLZ: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Related Industries: Biotechnology

Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive cancer that begins within the brain. Initially, signs and symptoms of glioblastoma are non-specific. They may include headaches, personality changes, nausea, and symptoms similar to those of a stroke. Worsening of symptoms often is rapid. This may progress to unconsciousness.The cause of most cases is unclear. Uncommon risk factors include genetic disorders such as neurofibromatosis and Li–Fraumeni syndrome, and previous radiation therapy. Glioblastomas represent 15% of brain tumors. They can either start from normal brain cells or develop from an existing low-grade astrocytoma. The diagnosis typically is made by a combination of CT scan, MRI scan, and tissue biopsy.There is no clear way to prevent the disease. Typically, treatment involves surgery, after which chemotherapy and radiation therapy are used. The medication temozolomide is used frequently as part of chemotherapy. High dose steroids may be used to help reduce swelling and decrease symptoms. It is unclear whether trying to remove all or simply most of the cancer is better.Despite maximum treatment, the cancer usually recurs. The most common length of survival following diagnosis is 12 to 15 months, with fewer than 3% to 5% of people surviving longer than five years. Without treatment, survival is typically three months. It is the most common cancer that begins within the brain and the second most common brain tumor, after meningioma. About 3 per 100,000 people develop the disease a year. It most often begins around 64 years of age and occurs more commonly in males than females. Immunotherapy is being studied.

More about Glioblastoma
Browse All Tags